{"content":[{"text":"June 8, 2021","bbox":{"left":0.098039,"top":0.06867,"width":0.113157,"height":0.016926999999999998}},{"text":"NeuBase Therapeutics Demonstrates \n Functional Rescue in Myotonic Dystrophy \n Type 1 Model and Allele-Selective \n Inhibition of KRAS Mutations to Inhibit \n Tumor Growth","bbox":{"left":0.098039,"top":0.129764,"width":0.782227,"height":0.174006}},{"text":"Data presented today at NeuBase’s R&D Day show functional rescue of myotonic \n dystrophy type 1 (DM1) phenotype in vivo after subcutaneous dosing; positions \n program to enter the clinic in CY 2022 \n Company also presented data demonstrating selective reduction of mutant huntingtin \n protein in the brain after subcutaneous dosing in zQ175 Huntington’s disease mouse \n model \n Company unveiled new oncology program targeting KRAS G12D and G12V, the two \n most common and historically “undruggable” KRAS driver mutations; data show initial \n compounds are allele selective and inhibit tumor growth in KRAS-mutant tumor \n xenograft models \n These three programs highlight the broad potential of NeuBase’s PATrOL™ precision \n genetic medicine platform to scale across many diseases and address root causality \n via multiple mechanisms","bbox":{"left":0.147059,"top":0.325299,"width":0.7553799999999999,"height":0.23283600000000004}},{"text":"PITTSBURGH, June 08, 2021 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. \n (Nasdaq: NBSE) (\"NeuBase\" or the \"Company\"), a biotechnology company accelerating the \n genetic revolution using a new class of precision genetic medicines, today announced \n positive new data and program updates for its development pipeline of PATrOL-enabled \n genetic medicines.","bbox":{"left":0.098039,"top":0.574352,"width":0.804467,"height":0.088897}},{"text":"Dietrich A. Stephan, Ph.D., Chairman and CEO of NeuBase Therapeutics, said, “The data \n presented today from several programs in our pipeline highlight the unique potential of our \n PATrOL technology platform to generate new precision genetic medicines for a wide range \n of diseases with an incomparable flexibility to target distinctive gene dysfunctions. We \n successfully demonstrated that our platform can therapeutically modulate in vivo gene \n function at the DNA or RNA level with exquisite precision of target engagement in three \n different disease indications with different mechanisms of disease. These data show how we \n can utilize the PATrOL platform to design drug candidates to inhibit DNA transcription, RNA \n translation, and mutant protein production, as well as displace bound proteins to rescue mis- \n splicing.”","bbox":{"left":0.098039,"top":0.679466,"width":0.8042090000000001,"height":0.17885799999999996}},{"text":"Dr. Stephan continued, “We have made significant progress since our last data release, \n showing functional rescue in myotonic dystrophy type 1 after subcutaneous dosing, in vivo \n proof of concept in Huntington’s disease with allele-selective mutant protein knock-down \n after getting compounds across the blood-brain barrier following systemic dosing, and initial","bbox":{"left":0.098039,"top":0.874541,"width":0.804314,"height":0.070905}}],"images_bbox":[{"left":0.656863,"top":0.068182,"width":0.245098,"height":0.041667}],"images_bbox_not_text_overlap":[{"left":0.656863,"top":0.068182,"width":0.245098,"height":0.041667}]}